Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart), ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

The U.S. Food and Drug Administration (USFDA) on Friday approved Merilog as biosimilar to Novolog (insulin aspart) for the ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

The Republican-controlled State Senate has joined the DFL-controlled House to advance a proposed emergency insulin bill. In mid-February, the Minnesota Senate established a plan to give ...

Life Sciences Ontario (LSO) proudly announces the recipients of the 2025 LSO Awards, celebrating excellence and innovation in life sciences. Now in its 22nd year, the LSO Awards continues its ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...